Trimel Pharmaceuticals has named Tom Rossi as CEO to replace Bruce D. Brydon, who has stepped down as CEO. Rossi has been President of Trimel since he joined the company in August 2011 and also became Chief Operating Officer in March 2012.
Brydon, who will continue as chairman of the board of directors, commented, “After 18 months as a reporting issuer on the Toronto Stock Exchange, it was time to take the next step in the development of the Company and separate the roles of the Chairman and the Chief Executive Officer. Trimel’s realigned governance structure is consistent with best practices of corporate governance.”
Brydon also noted that, “This realignment occurs along an easily identifiable transition point, with CompleoTRT having completed its pivotal Phase 3 trial, the results of which meets the FDA’s required endpoints, and Tefina in Phase 2 clinical development, potentially placing Trimel at the forefront of resolving a significant unmet need in women’s health. With both of these products now in advanced development, I believe I have fulfilled my original mandate to our shareholders.”
CompleoTRT, formerly known as TBS-1, is an intranasal gel formulation of testosterone for the treatment of male menopause. Tefina, formerly known as TBS-2, is an intranasal low-dose gel formulation of testosterone for the treatment of female sexual dysfunction. The company also has a unit-dose dry powder inhalation platform called TriVair.
Read the Trimel press release.
